Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)

被引：169
作者：
Locatelli, Francesco [1 ]
Covic, Adrian [2 ]
Eckardt, Kai-Uwe [3 ]
Wiecek, Andrzej [4 ]
Vanholder, Raymond [5 ]
机构：
[1] Alessandro Manzoni Hosp, Dept Nephrol Dialysis & Renal Transplantat, I-23900 Lecce, Italy
[2] Univ Med Gr T Popa, CI Parhon Univ Hosp, Dept Nephrol Dialysis & Transplantat, Iasi, Romania
[3] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Nurnberg, Germany
[4] Med Univ Silesia, Dept Nephrol Endocrinol & Metab Dis, Katowice, Francuska, Poland
[5] Ghent Univ Hosp, Nephrol Sect, B-9000 Ghent, Belgium
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2009年 / 24卷 / 02期
关键词：
ERYTHROPOIETIN RECEPTOR ACTIVATOR; RED-CELL APLASIA; EXTENDED ADMINISTRATION INTERVALS; CERA CORRECTS ANEMIA; GLYCOL-EPOETIN-BETA; ANTIERYTHROPOIETIN ANTIBODIES; PRACTICE GUIDELINES; STABLE HEMOGLOBIN; PERITONEAL-DIALYSIS; HEMODIALYSIS;
D O I：
10.1093/ndt/gfn653
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：348 / 354
页数：7
相关论文
共 48 条
  • [1] *AN WORK GROUP NAT, 1997, AM J KIDNEY DIS S, V30, P192
  • [2] [Anonymous], FDA Briefing Document Moderna Covid-19 Vaccine
  • [3] [Anonymous], 2007, FDA BRIEF DOC
  • [4] [Anonymous], 2001, Am J Kidney Dis, V37, pS1
  • [5] Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
    Bennett, CL
    Cournoyer, D
    Carson, KR
    Rossert, J
    Luminari, S
    Evens, AM
    Locatelli, F
    Belknap, SM
    McKoy, JM
    Lyons, EA
    Kim, B
    Sharma, R
    Costello, S
    Toffelmire, EB
    Wells, GA
    Messner, HA
    Yarnold, PR
    Trifilio, SM
    Raisch, DW
    Kuzel, TM
    Nissenson, A
    Lim, LC
    Tallman, MS
    Casadevall, N
    [J]. BLOOD, 2005, 106 (10) : 3343 - 3347
  • [6] Hemoglobin variability in epoetin-treated hemodialysis patients
    Berns, JS
    Elzein, H
    Lynn, RI
    Fishbane, S
    Meisels, IS
    DeOreo, PB
    [J]. KIDNEY INTERNATIONAL, 2003, 64 (04) : 1514 - 1521
  • [7] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    Besarab, A
    Bolton, WK
    Browne, JK
    Egrie, JC
    Nissenson, AR
    Okamoto, DM
    Schwab, SJ
    Goodkin, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) : 584 - 590
  • [8] The normal hematocrit study - Follow-up
    Besarab, Anatole
    Goodkin, David A.
    Nissenson, Allen R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (04) : 433 - 434
  • [9] Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
    Besarab, Anatole
    Salifu, Moro O.
    Lunde, N. Martin
    Bansal, Vinod
    Fishbane, Steven
    Dougherty, Frank C.
    Beyer, Ulrich
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (04) : 626 - 639
  • [10] Intravenous CERA maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study
    Canaud, Bernard
    Mingardi, Giulio
    Braun, Johann
    Aljama, Pedro
    Kerr, Peter G.
    Locatelli, Francesco
    Villa, Giuseppe
    Van Vlem, Bruno
    McMahon, Alan W.
    Kerloeguen, Cecile
    Beyer, Ulrich
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (11) : 3654 - 3661
12345